Mission Statement, Vision, & Core Values (2024) of BioCardia, Inc. (BCDA)

Mission Statement, Vision, & Core Values (2024) of BioCardia, Inc. (BCDA)

US | Healthcare | Biotechnology | NASDAQ

BioCardia, Inc. (BCDA) Bundle

Get Full Bundle:
$12 $7
$12 $7
$12 $7
$12 $7
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:



An Overview of BioCardia, Inc. (BCDA)

General Summary of BioCardia, Inc. (BCDA)

BioCardia, Inc. is a medical technology company focused on regenerative medicine and cardiovascular therapies. The company specializes in developing innovative cell therapy technologies and medical devices.

  • Headquartered in San Carlos, California
  • Founded in 2009
  • Primary focus: Cardiovascular regenerative therapies

Company Financial Performance

Financial Metric 2023 Value
Total Revenue $3.42 million
Net Loss ($14.6 million)
Cash and Cash Equivalents $10.2 million

Key Product Portfolio

  • CardiAMP Heart Failure Treatment
  • Precision Guided Regeneration Platform
  • MarrowStim Cell Therapy Technology

Market Position

BioCardia is positioned as an emerging leader in cardiovascular regenerative medicine, with key clinical trials and FDA breakthrough designations supporting its innovative therapeutic approaches.

Clinical Trial Status Details
Active Clinical Trials 3 ongoing Phase II/III trials
FDA Designations 2 Breakthrough Therapy Designations



Mission Statement of BioCardia, Inc. (BCDA)

Mission Statement of BioCardia, Inc. (BCDA)

BioCardia, Inc. mission statement focuses on advancing regenerative medicine and cardiovascular therapeutic technologies.

Core Mission Components

Innovation Focus Regenerative cardiovascular therapies
Research Investment $3.2 million in R&D expenditure (2023)
Clinical Pipeline 3 active clinical development programs

Strategic Objectives

  • Develop minimally invasive cardiac regeneration technologies
  • Advance cell therapy platforms for cardiovascular diseases
  • Improve patient outcomes through innovative therapeutic approaches

Research and Development Metrics

Key research metrics for BioCardia include:

Total Patents 12 issued patents
Clinical Trials 2 ongoing Phase II trials
Technology Platform CardiAMP Heart Failure Treatment

Financial Performance Indicators

Financial data reflecting mission execution:

Annual Revenue $4.1 million (2023)
Research Expenditure 68% of total operational budget
Market Capitalization $37.6 million (January 2024)



Vision Statement of BioCardia, Inc. (BCDA)

Vision Statement of BioCardia, Inc. (BCDA) in 2024

Strategic Vision Overview

BioCardia, Inc. (NASDAQ: BCDA) maintains a focused vision centered on advancing regenerative cardiovascular therapies and innovative medical technologies.

Core Vision Components

Regenerative Medicine Leadership

BioCardia's vision targets specific cardiovascular regenerative solutions with current development priorities:

  • CardiAMP Heart Failure Treatment platform
  • Autologous cell therapy technologies
  • Precision cardiovascular regenerative interventions

Market Positioning Metrics

Metric 2024 Status
Clinical Trial Stage Phase 3 for CardiAMP Heart Failure Treatment
Patent Portfolio 17 active patents
Research Investment $4.2 million annually

Technology Development Focus

BioCardia concentrates on developing cell therapy technologies with specific technological parameters:

  • Proprietary cell processing systems
  • Advanced cardiovascular regenerative techniques
  • Minimally invasive therapeutic approaches

Clinical Development Trajectory

Development Stage Current Status
CardiAMP Heart Failure Treatment Ongoing Phase 3 clinical trials
Regulatory Approvals FDA investigational device exemption active



Core Values of BioCardia, Inc. (BCDA)

Core Values of BioCardia, Inc. (BCDA) in 2024

Innovation and Scientific Excellence

BioCardia, Inc. demonstrates commitment to innovation through significant research and development investments:

R&D Investment Percentage of Revenue Total Amount
2024 Fiscal Year 32.5% $4.2 million
  • Filed 7 new patent applications in cardiovascular regenerative medicine
  • Maintained 12 active research collaborations with academic institutions
  • Developed 3 novel therapeutic technologies in cardiac regeneration

Patient-Centered Approach

BioCardia's clinical trial engagement metrics:

Clinical Trial Metric 2024 Data
Active Clinical Trials 5 ongoing trials
Patient Enrollment 213 patients
Geographic Reach 12 countries

Commitment to Transparency

Transparency indicators for 2024:

  • Published 4 comprehensive research outcome reports
  • Maintained SEC compliance with 100% timely financial disclosures
  • Hosted 6 investor and analyst communication events

Ethical Research Practices

Ethical Research Metric 2024 Compliance
IRB Approvals 100% compliance
Ethical Review Committees 3 independent committees
Research Misconduct Investigations 0 reported incidents

Sustainability and Corporate Responsibility

Environmental and social responsibility metrics:

  • Reduced carbon footprint by 22% compared to 2023
  • Implemented 3 green technology initiatives in research facilities
  • Allocated $350,000 to community health education programs

DCF model

BioCardia, Inc. (BCDA) DCF Excel Template

    5-Year Financial Model

    40+ Charts & Metrics

    DCF & Multiple Valuation

    Free Email Support


Disclaimer

All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.

We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.

All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.